Page last updated: 2024-10-30

mesalamine and Lymph Node Metastasis

mesalamine has been researched along with Lymph Node Metastasis in 1 studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Research Excerpts

ExcerptRelevanceReference
"The use of immunosuppressants for the treatment of nephrotic syndrome might affect the development of rectal carcinoma."1.43Ulcerative colitis associated with nephrotic syndrome after treatment with mesalazine developed into rectal carcinoma: a case study. ( Koketsu, S; Kubota, Y; Noie, T; Okuyama, T; Ono, Y; Oya, M; Sameshima, S, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sameshima, S1
Koketsu, S1
Okuyama, T1
Kubota, Y1
Ono, Y1
Noie, T1
Oya, M1

Other Studies

1 other study available for mesalamine and Lymph Node Metastasis

ArticleYear
Ulcerative colitis associated with nephrotic syndrome after treatment with mesalazine developed into rectal carcinoma: a case study.
    World journal of surgical oncology, 2016, Jul-22, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adolescent; Antineoplastic Agents; Colitis, Ulcerative; Colonoscopy; Humans; Lymphat

2016